Pharmaceutical companies are actively exploring the children's drug market, and some companies have raised nearly 297 million yuan

 In recent years, children's medicine has been continuously encouraged by national policies, such as the "China Children's Development Program (2021-2030)", "Implementation Plan for Implementing the 2021-2030 China Women's and Children's Development Program", "The Implementation of the Drug Administration Law of the People's Republic of China" The release of policies such as the Regulations (Draft for Comments)” has brought benefits to the development of children’s medicines
.
It is reported that the recent favorable policies for children's medicines have been welcomed.
The National Health and Health Commission issued the "Notice on Further Strengthening the Safety Management of Medication to Improve the Level of Rational Use of Drugs", emphasizing the protection of drug safety for key groups.
The total number of varieties is limited
.
 

Driven by favorable policies, children's medicines have ushered in development opportunities, and some pharmaceutical companies have also stepped up efforts to develop children's medicines and open up the children's medicine market
.
For example, Kangzhi Pharmaceutical recently announced that the company plans to raise no more than 297 million yuan, and the net amount of funds raised after deducting issuance expenses is planned to be used for children's drug research and development projects
.
 

According to the data, Kangzhi Pharmaceutical's main business covers pharmaceuticals, maternal and child health products, medical services and other fields
.
It is reported that in 2018, Kangzhi Pharmaceutical acquired Zhongshan Ai Nursing Daily Necessities Co.
, Ltd.
, and its business layout was extended to the maternal and infant health care sector
.

 

Another example is Sunflower Pharmaceuticals, which recently stated in the investor relations activity record sheet that it will continue to focus on over-the-counter drugs in the future and Rio Tinto's children's drug market
.
Sunflower Pharmaceutical said that starting from 2021, the company has gradually implemented some varieties of BD (business development) projects, acquired 6 children's drug varieties such as Shuanghuanglian Granules, and participated in patch companies, hoping to bring the company to the OTC side in the future.
Comes with continued variety supplementation
.
In terms of children's medicines, we have introduced products for children's rare diseases and neuropsychiatry, hoping to further expand the company's children's medicine market
.

 

　　Sunflower Pharmaceutical stated that children's medicine is the company's core strategic direction, and the field of children's health is also an important extension of the core strategy
.
At present, Sunflower Pharmaceutical's children's respiratory disease drug segment also gathers the company's major single product categories.
Currently, there are honeysuckle dew, Xiaoer Chaigui Ture Granules, Xiaoer Paracetamol Huangnamin Granules, and Xiaoer Feirekechuan Oral Liquid/ The sales of children's medicines such as granules and amoxicillin granules exceed 100 million yuan
.

 

　　Yipinhong Pharmaceutical also recently stated that the company has 22 children's drug registration approval documents and 17 children's drug projects under development around the layout of "special children's drugs + innovative chronic disease drugs + biological gene vaccines"
.
As a domestic company in the field of children's medicine, in the first half of 2022, Poinsettia Pharmaceuticals' investment in research and development increased by 33.
13% year-on-year to 70.
068 million yuan
.

 

　　It is reported that Yipinhong Pharmaceutical has a number of children's drug technology platforms.
Through technological innovations such as drug suspension technology, particle masking technology, and precise drug delivery, it can overcome clinical problems such as poor compliance with children's medication and many safety hazards, and accurately treat children.
patient disease
.
Its children's drug product structure is rich, which can meet the clinical diagnosis and treatment needs of common children's diseases in the fields of breathing, anti-infection, anti-allergy, and digestion, covering children of all ages from 0 to 14 years old
.
The company said that in the past two years, a series of favorable policies have greatly benefited the sales of poinsettia children's pharmaceutical products
.

 

　　In recent years, the issue of children's drug use has attracted the attention of the state.
In order to meet children's drug needs and ensure drug safety, the state has adopted a series of measures to encourage the development and production of children's drugs, alleviate the shortage of children's drugs, and ensure the safety of children's drugs
.
The industry said that it is believed that under the promotion of favorable national policies, more and more enterprises will actively join in, and the children's drug market will also usher in new changes
.